Exploring New Treatment Paradigms in Prostate Cancer: Current and Emerging Treatment Strategies to Improve Patient Care

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from June 1, 2020 to August 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Astellas and Medivation, Inc., a Pfizer company, AstraZeneca, and Merck Sharp & Dohme Corp.

Prostate cancer is the second leading cause of cancer deaths among American men, with an estimated 174,000 new cases diagnosed in 2019. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. A wide range of treatment options are available, from front-line to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers, and appropriate patient selection criteria in patients with prostate cancer have been produced and are being used to better treat the disease. The measurement of prostate-specific antigen (PSA) level has also recently improved the diagnosis of CRPC as it helps identify patients earlier, especially those that are undertreated.

The recent improvement of understanding biologics and molecular drivers of prostate cancer growth and progression resulted in the investigations of several novel targeted therapies, including androgen receptor inhibitor (ARI) targeting agents, antineoplastic agent and gonadotropin releasing hormone agonist, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors and proteasome inhibitors. There are also updated options for treatments being used to improve outcomes for hormone sensitive prostate cancer. Several of these options have either received approval from the FDA or are in late clinical trials. The understanding of current treatments is well studied, there continues to be advances in all stages of treatment paradigms in all stages of prostate cancer.

Upon completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of clinical data on current and emerging treatment strategies for prostate cancer

  • Discuss updates in the diagnosis of prostate cancer, including genetic mutations and biomarkers, which can be used for risk stratification and guide appropriate treatment selection

  • Assess different unmet needs and the evidence supporting the PARP inhibitor treatment options and outcomes for prostate cancer management

  • Examine recent evidence supporting the use of emerging treatment agents for the treatment of nonmetastatic prostate cancer

  • Explore the role of emerging agents for newly diagnosed metastatic hormone-sensitive prostate cancer

  • Develop strategies with a multidisciplinary team to improve adherence, manage adverse events and explore optimal care for patients with prostate cancer


Faculty: Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center


Dr. Smith serves as a consultant to Amgen, Astellas, Bayer, Janssen, Lilly, Novartis, and Pfizer. He has received grants/research support from Amgen, Bayer, Lilly, and Janssen. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Astellas and Medivation, Inc., a Pfizer company, AstraZeneca, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue